These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 28892524)

  • 1. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
    Wouters OJ; McKee M; Luyten J
    JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
    DeMartino PC; Miljkovic MD; Prasad V
    JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
    Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The distribution of sales revenues from pharmaceutical innovation.
    Grabowski HG; Vernon J
    Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014.
    Wouters OJ; Kesselheim AS; Kuha J; Luyten J
    Value Health; 2024 Oct; 27(10):1373-1381. PubMed ID: 38977188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
    Moore TJ; Zhang H; Anderson G; Alexander GC
    JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The high price of anticancer drugs: origins, implications, barriers, solutions.
    Prasad V; De Jesús K; Mailankody S
    Nat Rev Clin Oncol; 2017 Jun; 14(6):381-390. PubMed ID: 28290490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising.
    DiStefano MJ; Markell JM; Doherty CC; Alexander GC; Anderson GF
    JAMA; 2023 Feb; 329(5):386-392. PubMed ID: 36749334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.